The U.S. patent statue currently requires a patent specification to “contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains…to make and use the same[.]” At issue before the Court of Appeals for the Federal Circuit in Ariad Pharmaceuticals v. Eli Lilly is whether the “written description” requirement at the beginning of this sentence is a separate and distinct requirement from the “enablement” requirement recited in the latter part of the sentence. Finnegan partner Charles Lipsey, arguing on behalf of Eli Lilly, maintained that claims only describe the boundary of inventions, but not the inventions themselves.
Award/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Commentary
May 20, 2026
Award/Ranking
Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award
May 13, 2026
Press Release
Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination
May 11, 2026
Award/Ranking
Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey
May 7, 2026
Announcement
Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International
May 4, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.